21 research outputs found
Features of the integration of two-layer metal knitwear made of titanium nickelide during the replacement of a thoracoabdominal defect in the experiment
The aim of investigation was to study experimentally the morphological features of tissue integration of two-layer titanium nickelide (TiNi) knitwear when replacing thoracoabdominal defects.Materials and methods. The experiments were carried out on 40 Wistar rats. TheΒ experimental animals were divided into two comparison groups: in GroupΒ A (nΒ =Β 20) theΒ defect was replaced using a two-layer knitted tape made of TiNi, inΒ GroupΒ B (nΒ =Β 20) a polypropylene mesh implant was used. The technique of the operation and the peculiarities of keeping the animals did not differ. Animals were taken outΒ after 14, 30, 60 and 90Β days of experiment. The macroscopic structural features at the site of implant fixation to tissues and at the sites of contact with underlying organs were studied, and the inflammatory process was assessed. The histological and electron microscopic study was carried out with an assessment of the features of tissue integration through the mesh structure of knitwear.Results. Thirty days after the surgery in four cases of GroupΒ B the appearance ofΒ the chest wall deformation at the site of implant fixation was noted, in one case theΒ deformation site was located along the lateral edge of the abdominal wall. Among theΒ animals of GroupΒ A no such changes were recorded. The histological and electron microscopy examination revealed that the porous structure of theΒ TiNi wire, as well as the biomechanical and biochemical properties of the two-layer metal knitwear, ensure optimal integration of the endoprosthesis in the body tissues, forming anΒ elastic frame close to natural. In GroupΒ B, on the contrary, the reaction of theΒ body caused by the implanted polypropylene prosthesis was characterized byΒ more pronounced fibrosis, and tissue integration through the mesh structure ofΒ theΒ implant was not observed.Conclusion. Two-layer TiNi knitwear in the replacement of complex structures of the thoracoabdominal zone showed promising results, which opens up prospects for further clinical research
ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΠΎΠ½Π½Π°Ρ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ Π³Π΅Π½ΠΎΠ² ΡΠ΅ΠΌΠ΅ΠΉΡΡΠ²Π° ABC-ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ΅ΡΠΎΠ² ΠΈ Π³Π΅Π½ΠΎΠ² Ρ ΠΈΠΌΠΈΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π² ΠΎΠΏΡΡ ΠΎΠ»ΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·Π΅ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°Ρ Π² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ·Π»Ρ
Introduction. Metastatic tumors (particularly gastric cancer) have been found to be characterized by heterogeneity between the primary tumor and metastases. This type of heterogeneity comes to the fore when treating primary-metastatic forms of tumor and is an important reason for the low effectiveness of their treatment. In this regard, comparative analysis of ABC-transporter gene expression and chemosensitivity genes will allow to characterize to a certain extent the resistance and sensitivity of primary tumor, carcinomatosis and metastases to therapy and provide the basis for personalized treatment approach.Aim. To evaluate expression heterogeneity of ABC-transporter genes and chemosensitivity genes in gastric tumor, carcinomatosis and lymph node metastases.Materials and methods. Overall 41 patients with disseminated gastric cancer stage IV with carcinomatosis of peritoneum were included in the investigation. All patients underwent surgery according to Roux palliative gastrectomy. After surgery patients underwent chemotherapy depending on indications. RNA was isolated using RNeasy Plus mini kit (Qiagen, Germany). The expression level of ABC transporter genes (ABCB1, ABCC1, ABCC2, ABCC5, ABCG1, ABCG2) and chemosensitivity genes (BRCA1, RRM1, ERCC1, TOP1, TOP2Ξ±, TUBΞ²3, TYMS, GSTP1) was assessed by reverse transcription polymerase chain reaction (RT-PCR) in primary tumor, carcinomatosis and lymph node metastases.Results. The expression levels of the genes under study were shown to vary widely. For ABC transporter genes, ABCG1 (3.1 Β± 1.1; max 32.0), ABCG2 (7.9 Β± 2.3; max 54.1), ABCG2 (9.6 Β± 3.8; max 101.0) were the most expressed genes in gastric tumor tissue, carcinomatosis and lymph node metastasis, respectively. Hyperexpression among chemosensitivity genes at all three sites was characteristic only of TOP2Ξ± (17.2 Β± 6.0; max. 161.9; 10.8 Β± 4.1; max. 105.1; 35.3 Β± 0.8; max. 439.6, respectively). We found that TOP2Ξ± and BRCA1 gene expression levels were higher in lymph node metastasis compared with gastric tumor tissue and carcinomatosis (at p = 0.005 and p = 0.001). Whereas ABCC1 gene expression was statistically significantly higher in carcinomatosis (p = 0.03).Conclusion. Thus, a high level of expression heterogeneity is observed in gastric cancer, which affects the expression patterns of various genes in different localizations. The expression profile can be used to determine the level of heterogeneity and approach to personalized therapy tactics.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΎΠΏΡΡ
ΠΎΠ»ΡΠΌ (Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ ΡΠ°ΠΊΡ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°) ΡΠ²ΠΎΠΉΡΡΠ²Π΅Π½Π½Π° Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΡΠΌΠΈ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΎΡΠ°Π³Π°ΠΌΠΈ. Π’Π°ΠΊΠΎΠΉ ΡΠΈΠΏ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠΈΡΠΈΠ½ΠΎΠΉ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΏΠΎΡΡΠΎΠΌΡ Π΅Π³ΠΎ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΡΡΠΈΡΡΠ²Π°ΡΡ ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΠΌ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² ABC-ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ΅ΡΠΎΠ² ΠΈ Π³Π΅Π½ΠΎΠ² Ρ
ΠΈΠΌΠΈΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ Π² ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΠΎΠΉ ΠΌΠ΅ΡΠ΅ ΠΎΡ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°ΡΡ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡ ΠΈ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·Π° ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ² ΠΊ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ Π΄Π°ΡΡ ΠΎΡΠ½ΠΎΠ²Ρ Π΄Π»Ρ ΠΏΠ΅ΡΡΠΎΠ½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ.Π¦Π΅Π»Ρ β ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΎΠ½Π½ΠΎΠΉ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ Π³Π΅Π½ΠΎΠ² ABC-ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ΅ΡΠΎΠ² ΠΈ Π³Π΅Π½ΠΎΠ² Ρ
ΠΈΠΌΠΈΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π² ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·Π΅ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°Ρ
Π² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ·Π»Ρ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ 41 Π±ΠΎΠ»ΡΠ½ΠΎΠΉ Ρ Π΄ΠΈΡΡΠ΅ΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° IV ΡΡΠ°Π΄ΠΈΠΈ Ρ ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·ΠΎΠΌ Π±ΡΡΡΠΈΠ½Ρ. ΠΡΠ΅ΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΠΎΠΏΠ΅ΡΠ°ΡΠΈΡ Π² ΠΎΠ±ΡΠ΅ΠΌΠ΅ ΠΏΠ°Π»Π»ΠΈΠ°ΡΠΈΠ²Π½ΠΎΠΉ Π³Π°ΡΡΡΡΠΊΡΠΎΠΌΠΈΠΈ ΠΏΠΎ Π Ρ. ΠΠΎΡΠ»Π΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π° Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΠΎ ΡΡ
Π΅ΠΌΠ°ΠΌ GemCap + Π‘, FOLFIRI + Π‘, XELIRI + C, PC. Π ΠΠ Π²ΡΠ΄Π΅Π»ΡΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π½Π°Π±ΠΎΡΠ° RNeasy Plus mini Kit (Qiagen, ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ). Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² ABC-ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ΅ΡΠΎΠ² (ABCB1, ABCC1, ABCC2, ABCC5, ABCG1, ABCG2) ΠΈ Π³Π΅Π½ΠΎΠ² Ρ
ΠΈΠΌΠΈΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ (BRCA1, RRM1, ERCC1, TOP1, TOP2Ξ±, TUBΞ²3, TYMS, GSTP1) Π² ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·Π΅ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π΅ Π² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ·Π»Ρ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Ρ ΠΎΠ±ΡΠ°ΡΠ½ΠΎΠΉ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠ΅ΠΉ (ΠΠ’-ΠΠ¦Π ).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
Π³Π΅Π½ΠΎΠ² ΡΠΈΠ»ΡΠ½ΠΎ Π²Π°ΡΡΠΈΡΡΠ΅Ρ. ΠΠ· Π³Π΅Π½ΠΎΠ² ABC-ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ΅ΡΠΎΠ² Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π΄Π»Ρ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·Π° ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π° Π² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ·Π»Ρ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π΄Π»Ρ ABCG1 (3,1 Β± 1,1; max 32,0), ABCG2 (7,9 Β± 2,3; max 54,1) ΠΈ ABCG2 (9,6 Β± 3,8; max 100,9) ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. Π‘ΡΠ΅Π΄ΠΈ Π³Π΅Π½ΠΎΠ² Ρ
ΠΈΠΌΠΈΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π³ΠΈΠΏΠ΅ΡΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π² ΡΡΠΈΡ
ΡΠΊΠ°Π½ΡΡ
Π±ΡΠ»Π° Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½Π° ΡΠΎΠ»ΡΠΊΠΎ Π΄Π»Ρ TOP2Ξ± (17,2 Β± 5,9; max 161,9; 10,8 Β± 4,1; max 105,1; 35,3 Β± 0,8; max 439,6 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² TOP2Ξ± ΠΈ BRCA1 Π²ΡΡΠ΅ Π² ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°Ρ
Π² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»Π°Ρ
ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΊΠ°Π½ΡΡ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° ΠΈ ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·ΠΎΠΌ (p = 0,005 ΠΈ p = 0,001 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ), ΡΠΎΠ³Π΄Π° ΠΊΠ°ΠΊ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π³Π΅Π½Π° ABCC1 ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ Π²ΡΡΠ΅ Π² ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·Π΅ (p = 0,03).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΠΏΡΠΎΡΠ»Π΅ΠΆΠΈΠ²Π°Π΅ΡΡΡ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΎΠ½Π½ΠΎΠΉ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, Π²Π»ΠΈΡΡΡΠ΅ΠΉ Π½Π° ΠΏΠ°ΡΡΠ΅ΡΠ½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³Π΅Π½ΠΎΠ² Π² ΡΠ°Π·Π½ΡΡ
Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡΡ
. Π’ΠΎΡΠ½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ»Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
Π³Π΅Π½ΠΎΠ² Π² ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°Ρ
ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΠΏΠΎΠ΄ΠΎΠ±ΡΠ°ΡΡ ΡΠ°ΠΊΡΠΈΠΊΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΡΡ
Π΅ΠΌΡ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅ Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡΡ Π±ΡΠ΄ΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Ρ Π² ΠΊΠ°ΠΆΠ΄ΠΎΠΌ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΠΎΠΌ ΡΠ»ΡΡΠ°Π΅
Spatial and temporal trends of the Stockholm Convention POPs in mothersβ milkΒ βΒ a global review
Π Π°ΠΊ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°: ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Ρ ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΈ ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·Π΅ Π±ΡΡΡΠΈΠ½Ρ (Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΠΉ ΠΎΠ±Π·ΠΎΡ)
Gastric cancer (gc) is one of the most common cancers worldwide. The majority of newly diagnosed gastric cancer cases present with distant metastases. Peritoneal carcinomatosis (pc) is the most unfavorable type of progression of primary gc, which occurs in 14β43 % of patients. The purpose of the study was to highlight modern approaches to the treatment of gc with pc. Material and methods. We analyzed 136 publications available from pubmed, medline, cochrane library, and elibrary databases. The final analysis included 46 studies that met the specified parameters. Results. The modern approaches to the treatment of gc with peritoneal carcinomatosis were reviewed, namely: cytoreductive surgery (crs), combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (crs/hipec); neoadjuvant intraperitoneal/systemic chemotherapy (nips) and pressurized intraperitoneal aerosol chemotherapy (pipac). The results of large randomized trials and meta-analyses were analyzed. Benefits and limitations of these trials were assessed. Conclusion. The peritoneal cancer index (pci) and the level of cytoreduction are two key prognostic factors for increasing the median overall survival. By reducing tumor volume through cytoreductive surgery, it is possible to allow tumor cells to re-enter the proliferative phase of the cell cycle and make them more sensitive to antitumor agents. The hematoperitoneal barrier is the main reason that prevents the effective delivery of drugs from the systemic bloodstream to the abdominal cavity, which is why the effect of systemic chemotherapy on peritoneal metastases is extremely limited. Intraperitoneal chemotherapy offers a more effective and intensive regional therapy, creating a so-called Β«depotΒ» of a chemotherapy drug, thereby prolonging the effect of the administered drugs. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (crs + hipec) using the combination of surgical resection, cytotoxic chemotherapy, hyperthermic ablation of the tumor and hydrodynamic flushing, is a promising approach in the treatment of gc with peritoneal carcinomatosis.Π Π°ΠΊ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° (Π Π) ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΡΠ°ΠΌΡΡ
ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΡ
ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ Π² ΠΌΠΈΡΠ΅. Π£ 50β65 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π Π, Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ ΠΈΠΌΠ΅ΡΡΡΡ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΠ΅ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Ρ. ΠΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ· Π±ΡΡΡΠΈΠ½Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΠΈ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΉ Π²ΠΈΠ΄ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ Π Π, ΠΊΠΎΡΠΎΡΡΠΉ Π²ΡΡΡΠ΅ΡΠ°Π΅ΡΡΡ Ρ 14β43 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ²Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° Ρ ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΡΠΌ ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·ΠΎΠΌ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΠΈΡΠΊ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² Π±ΡΠ» ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ Π² ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΡ
ΡΠΈΡΡΠ΅ΠΌΠ°Ρ
pubmed, medline, cochrane library, elibrary. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠΈΡΠΊΠ° ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ Π±ΡΠ»ΠΎ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ 136 ΡΡΠ°ΡΠ΅ΠΉ, ΠΏΠΎ ΠΈΠ·ΡΡΠ°Π΅ΠΌΠΎΠΉ ΡΠ΅ΠΌΠ°ΡΠΈΠΊΠ΅. Π ΠΎΠΊΠΎΠ½ΡΠ°ΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π²ΠΎΡΠ»ΠΈ 46 ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
Π·Π°Π΄Π°Π½Π½ΡΠΌ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½ ΠΎΠ±Π·ΠΎΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ Π Π Ρ ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·ΠΎΠΌ Π±ΡΡΡΠΈΠ½Ρ: cRs β ΡΠΈΡΠΎΡΠ΅Π΄ΡΠΊΡΠΈΠ²Π½Π°Ρ Ρ
ΠΈΡΡΡΠ³ΠΈΡ, Hipec β ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΡΠΈΡΠΎΡΠ΅Π΄ΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Ρ
ΠΈΡΡΡΠ³ΠΈΠΈ ΠΈ ΠΈΠ½ΡΡΠ°ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π²Π½ΡΡΡΠΈΠ±ΡΡΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅ΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ; Π½Π΅ΠΎΠ°Π΄ΡΡΠ²Π°Π½ΡΠ½Π°Ρ Π²Π½ΡΡΡΠΈΠ±ΡΡΡΠ½Π°Ρ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ (Nips) ΠΈ pipac β Π²Π½ΡΡΡΠΈΠ±ΡΡΡΠ½Π°Ρ Π°ΡΡΠΎΠ·ΠΎΠ»ΡΠ½Π°Ρ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΠΎΠ΄ Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅ΠΌ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΊΡΡΠΏΠ½ΡΡ
ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈ ΠΌΠ΅ΡΠ°Π°Π½Π°Π»ΠΈΠ·ΠΎΠ², Ρ ΠΎΡΠ΅Π½ΠΊΠΎΠΉ ΠΈΡ
ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ² ΠΈ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΠΉ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ½Π΄Π΅ΠΊΡ ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°Π½ΡΠ΅ΡΠΎΠΌΠ°ΡΠΎΠ·Π° (pci) ΠΈ ΡΡΠ΅ΠΏΠ΅Π½Ρ ΡΠΈΡΠΎΡΠ΅Π΄ΡΠΊΡΠΈΠΈ (ccR), ΡΠ²Π»ΡΡΡΡΡ Π΄Π²ΡΠΌΡ ΠΊΠ»ΡΡΠ΅Π²ΡΠΌΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ Π΄Π»Ρ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ. Π£ΠΌΠ΅Π½ΡΡΠΈΠ² ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΠΌΠ°ΡΡΡ Π·Π° ΡΡΠ΅Ρ ΡΠΈΡΠΎΡΠ΅Π΄ΡΠΊΡΠΈΠΈ, ΠΌΠΎΠΆΠ½ΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΌ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎ Π²ΠΎΠΉΡΠΈ Π² ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΡΡ ΡΠ°Π·Ρ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΊΠ»Π° ΠΈ, Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ, ΡΠ΄Π΅Π»Π°ΡΡ ΠΈΡ
Π±ΠΎΠ»Π΅Π΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΠΊ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΌ Π°Π³Π΅Π½ΡΠ°ΠΌ. ΠΠ΅ΠΌΠ°ΡΠΎΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΡΠΉ Π±Π°ΡΡΠ΅Ρ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΠΏΡΠΈΡΠΈΠ½ΠΎΠΉ, ΠΊΠΎΡΠΎΡΠ°Ρ ΠΏΡΠ΅ΠΏΡΡΡΡΠ²ΡΠ΅Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π΄ΠΎΡΡΠ°Π²ΠΊΠ΅ Π»Π΅ΠΊΠ°ΡΡΡΠ² ΠΈΠ· ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΡΠΎΠΊΠ° Π² Π±ΡΡΡΠ½ΡΡ ΠΏΠΎΠ»ΠΎΡΡΡ, ΠΈΠ·-Π·Π° ΡΠ΅Π³ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π° ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΡΠ΅ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Ρ ΠΊΡΠ°ΠΉΠ½Π΅ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΎ. ΠΠ½ΡΡΡΠΈΠ±ΡΡΡΠ½Π°Ρ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΡΠ΅Π΄Π»Π°Π³Π°Π΅Ρ Π±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ ΠΈ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΡΡ ΡΠ΅Π³ΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ, ΡΠΎΠ·Π΄Π°Π²Π°Ρ ΡΠ°ΠΊ Π½Π°Π·ΡΠ²Π°Π΅ΠΌΠΎΠ΅ Β«Π΄Π΅ΠΏΠΎΒ» Ρ
ΠΈΠΌΠΈΠΎΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, ΠΈ ΡΠ΅ΠΌ ΡΠ°ΠΌΡΠΌ ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠΎΠ²Π°ΡΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π²Π²ΠΎΠ΄ΠΈΠΌΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². Π¦ΠΈΡΠΎΡΠ΅Π΄ΡΠΊΡΠΈΠ²Π½Π°Ρ Ρ
ΠΈΡΡΡΠ³ΠΈΡ Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅ΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π²Π½ΡΡΡΠΈΠ±ΡΡΡΠ½ΠΎΠΉ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ (cRs + Hipec) Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π Π Ρ ΠΠ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π·Π΅ΠΊΡΠΈΠΈ, ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π³ΠΈΠΏΠ΅ΡΡΠ΅ΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°Π±Π»ΡΡΠΈΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ Π³ΠΈΠ΄ΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠΎΠΌΡΠ²ΠΊΠΈ ΠΏΡΠ΅Π΄Π»Π°Π³Π°Π΅Ρ ΠΌΠ½ΠΎΠ³ΠΎΠΎΠ±Π΅ΡΠ°ΡΡΠΈΠ΅ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π°